 |
 |
Power3 Medical Continues Validation of NuroPro As Diagnostic Tool Aug 6, 2004 (financialwire.net via COMTEX) -- (FinancialWire) Power3 Medical Products, Inc. (PWRM) said it is continuing the validation of the NuroPro(TM) as a diagnostic tool in the early stage assessment of the diagnosis and progression of ALS, Alzheimer's, Parkinson's, and other neurodegenerative diseases. In support of the exclusive worldwide license agreement recently signed between Baylor College of Medicine and Power3 Medical, Dr. Stan Appel has agreed to provide additional patient samples to continue the ongoing validation program. This proteomic analysis of patient samples utilizing the NuroPro is supplemental to current assessments performed by Dr. Appel in patients' diagnosis. As of today, 219 samples have been analyzed with results above expectations. According to Dr. Ira Goldknopf, "The ongoing clinical validation of the NuroPro has shown great promise as a tool for assessment of neurodegenerative disease. The NuroPro, being used in comparison with current assessment by Dr. Appel as a diagnostic tool, demonstrates its accuracy and potential for use in early diagnosis. It is rewarding to see our proprietary technology being evaluated concurrently with the diagnosis of patients." Power 3 Medical Products is enrolled in Investrend Research's unique and pioneering professional analyst program, which facilitates independent analysts to provide financial coverage for shareholders and investors in companies that otherwise would have little or no analyst following. Investrend Research analyst Ryan Fuhrmann, CFA, is preparing a Criterion Research report. The Investrend Research program is the largest in the world and includes a number of safeguards to reduce or eliminate conflict. These systems, including media coverage and endorsements, may be accessed at http://www.investrendresearch.com Investrend Research subscribes to the "Standards for Independent Research Providers" at http://www.firstresearchconsortium.com, and adheres to the Guidelines for independent providers jointly endorsed by the National Investor Relations Institute (http://www.niri.org) and the Association for Investment Management and Research (http://www.aimr.org). The Dow Jones Newswires has stated that independent research has been growing in credibility over the past 18 months, specifically citing Investrend Research, and the New York Times has reported a survey by Charles Schwab & Co. reveals an astonishing 78 percent of active stockholders now "value research from independent firms over analysis by Wall Street firms with financial ties to the companies they are rating." A survey at Investopedia reveals that 74.7% of investors say that "legitimate fee-based research is objective and useful," and 70.9% say that a company that enrolls for "legitimate fee-based research is making a positive statement about its investment potential." Enrollment fees for Criterion coverage are $8,940, and the fees were paid by Focus Partners, LLC. There are never any fees associated with FinancialWire, which independently covers a wide range of corporate news, including but not limited to those that are or have been enrolled in Investrend's platforms. Complete information about any company enrolled in an Investrend shareholder empowerment platform, including those of its affiliates and independent analysts and webcasters, including disclosures and disclaimers, is available at the company's InvestorPower page at http://www.investrend.com/company/list.asp?sPathParam=yes , and on each report and press release, and investors are advised to read those disclosures carefully before trading in the equities of any enrolled company. For up-to-the-minute news, features and links click on http://www.financialwire.net FinancialWire is an independent, proprietary news service of Investrend Information, a division of Investrend Communications, Inc. It is not a press release service and receives no compensation for its news or opinions. Other divisions of Investrend, however, provide shareholder empowerment platforms such as forums, independent research and webcasting. For more information or to receive the FirstAlert daily summary of news, commentary, research reports, webcasts, events and conference calls, click on http://www.investrend.com/contact.asp The FinancialWire NewsFeed is now available in multiple formats to your site or desktop, free. Click on: http://www.investrend.com/XmlFeeds?level=268 FinancialWire http://www.financialwire.net For more information on Parkinson's and other movement disorders, go to Worldwide Education and Awareness for Movement Disorders at http://www.wemove.org For additional information about dystonia, go to http://www.spasmodictorticollis.org SOURCE: Investor's Business Daily http://www.investors.com/breakingnews.asp?journalid=22542131&brk=1 * * * Related References: The Breast Cancer NAFTest is Power3 Medical's initial breast cancer product developed in collaboration with the University of Texas MD Anderson Cancer Center. The test utilizes fluids from the breast called nipple aspirates to identify groups of breast cancer proteins. The collection of the nipple aspirate fluid is a non- invasive procedure utilizing a modified breast pump to obtain a drop of fluid from the nipple. The aspirate is analyzed to identify the specific breast cancer protein footprints. Power3 believes this test is the first test of its type that detects breast cancer earlier than any technologies currently allow. The initial proof-of-concept has been completed with remarkable effectiveness and sensitivity. Clinical trial preparation is currently underway. http://www.power3medical.com/products/naftest.aspx?level=0: The NuroPro Blood Test is Power3’s diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 9 proteins in blood serum to accurately detect and distinguish between Alzheimer’s disease, ALS (Lou Gehrig’s disease), and Parkinson’s disease . Early detection of these diseases will allow physicians to intervene at an early stage to delay disease progression, potentially allowing patients to outlive their debilitating symptoms. The NuroPro Test is currently in the development stages. The company has completed proof-of-concept and first stage of clinical validation studies, with results exceeding expectations. The validation is done in collaboration with Dr. Stan Appel, Chairman of the Department of Neurology at Baylor College of Medicine. http://www.power3medical.com/products/nuroprotest.aspx?level=1 How It Works Neurodegenerative disease, such as Alzheimer’s, ALS, and Parkinson’s disease attack the Nervous system, causing healthy cells to deteriorate and die. When a cell dies, certain proteins are released into the blood stream. Power3’s NuroPro Test monitors the concentration of these proteins to determine which neurodegenerative disease, if any, is afflicting the patient. http://www.power3medical.com/products/ndwork.aspx?level=10 Parkinson’s disease is a progressive and degenerative neurological disorder involving the loss of nervous tissue in the brain. When these motor neurons die or become impaired, the patient becomes unable to direct or control movement in a normal manner. Behavior is typically characterized by the following motor symptoms: Rigidity: stiffness or inflexibility of the limbs and joints Bradykinesia/akinesia: slowness of movement/absence of movement Tremor: involuntary, regular, rhythmic shaking of a limb, the head, the mouth, the tongue, or the entire body Postural instability: impaired balance and coordination A variety of medications provide relief from the symptoms, but no drug can stop the progression of the disease. In some cases, surgery is an appropriate treatment. Physical therapy and muscle strengthening exercised are also recommended by physicians. http://www.power3medical.com/products/parki.aspx?level=122 * * * ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn